RecruitingMetastatic Castration-Resistant Prostate Cancer
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
Eligible age
18+ yrs
Accepts
Men
Locations
10 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.
Sponsor: AstraZeneca
Where it's recruiting
California
Palo Alto · San Diego
Florida
Miami · Tampa
Illinois
Chicago
Louisiana
Metairie
Massachusetts
Boston
Minnesota
Rochester
Nebraska
Omaha
New York
New York
Ohio
Cleveland
Oregon
Portland
Source: ClinicalTrials.gov · NCT06879041 · last updated 2026-05-12